Vertex-UK
Vertex-UK is a global biotechnology company that researches, develops, and manufactures medicines for people with serious diseases.
The UK Home Office lists Vertex-UK as a licensed sponsor (A-rated, Global Business Mobility: Senior or Specialist Worker and Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. Home Office figures released under the Freedom of Information Act show Vertex-UK assigned 85 Certificates of Sponsorship in 2021–24 and 18 in 2025 for Skilled Worker and Global Business Mobility visas. We're showing 19 of their current openings.
Sponsor licence details
Sourced from the UK Home Office register of licensed sponsors.
Sponsorship history
Certificates of Sponsorship Vertex-UK assigned each year, from Home Office figures released under the Freedom of Information Act.
Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.
Licence timeline Pro
Every change we've seen on the Home Office register for Vertex-UK, and what its recent adverts say about sponsorship.
See this employer's full licence history: when it was licensed, rating and route changes, and when it last offered sponsorship in an advert.
Unlock with ProLicensed entities
2 UK-registered entities listed on the Home Office sponsor register.
About Vertex-UK
Vertex-UK is a global biotechnology company that focuses on scientific innovation to discover and develop medicines for people with serious diseases. Founded in 1989, the company specialises in therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain.
The business also maintains a pipeline of investigational therapies across several other serious conditions. These clinical and research programmes target neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes mellitus, and myotonic dystrophy type 1.
Open roles
19 live positions matched to this sponsor licence.